NEUROTECHPHARMACEUTICALS.COM: Keyword Density Checker

Total words: 1560 | 2-word phrases: 401 | 3-word phrases: 435 | 4-word phrases: 453

PAGE INFO

Title	Try to keep the title under 60 characters (72 characters) Encapsulated Cell Therapy \| Neurotech Pharmaceuticals, Inc. \| Cumberland
Description	Try to keep the meta description between 50 - 160 characters (132 characters) Neurotech Pharmaceuticals delivers MacTel treatment solutions, MacTel clinical trials, and MacTel Implant Encapsulated Cell Therapy.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (31 characters) Neurotech Pharmaceuticals, Inc.

#	Keyword	Frequency	Density
1	read more neurotech	5	1.15%
2	encapsulated cell therapy	3	0.69%
3	2023 read more	3	0.69%
4	skip to main	2	0.46%
5	more neurotech chief	2	0.46%
6	cell therapy ect	2	0.46%
7	type 2 mactel	2	0.46%
8	authors article in	2	0.46%
9	officer authors article	2	0.46%
10	neurotech chief medical	2	0.46%
11	our encapsulated cell	2	0.46%
12	2022 read more	2	0.46%
13	neurotech pharmaceuticals inc	2	0.46%
14	more neurotech pharmaceuticals	2	0.46%
15	on our encapsulated	2	0.46%
16	2024 read more	2	0.46%
17	for macular telangiectasia	2	0.46%
18	macular telangiectasia type	2	0.46%
19	map pin icon	2	0.46%
20	telangiectasia type 2	2	0.46%
21	sciencetechnology clinical patients	2	0.46%
22	clinical patients news	2	0.46%
23	medical officer authors	1	0.23%
24	contrast light backgroundlight	1	0.23%
25	appointment of scott	1	0.23%
26	the appointment of	1	0.23%
27	contrastnegative contrast light	1	0.23%
28	with the appointment	1	0.23%
29	expands executive team	1	0.23%
30	inc expands executive	1	0.23%

#	Keyword	Frequency	Density
1	our encapsulated cell therapy	2	0.44%
2	sciencetechnology clinical patients news	2	0.44%
3	read more neurotech pharmaceuticals	2	0.44%
4	2023 read more neurotech	2	0.44%
5	on our encapsulated cell	2	0.44%
6	encapsulated cell therapy ect	2	0.44%
7	read more neurotech chief	2	0.44%
8	more neurotech chief medical	2	0.44%
9	macular telangiectasia type 2	2	0.44%
10	for macular telangiectasia type	2	0.44%
11	telangiectasia type 2 mactel	2	0.44%
12	officer authors article in	2	0.44%
13	with the appointment of	1	0.22%
14	inc expands executive team	1	0.22%
15	pharmaceuticals inc expands executive	1	0.22%
16	the appointment of scott	1	0.22%
17	neurotech pharmaceuticals inc expands	1	0.22%
18	lead director september 13	1	0.22%
19	more neurotech pharmaceuticals inc	1	0.22%
20	of scott hunter as	1	0.22%
21	as lead director september	1	0.22%
22	board as lead director	1	0.22%
23	neurotech’s board as lead	1	0.22%
24	to neurotech’s board as	1	0.22%
25	appointed to neurotech’s board	1	0.22%
26	gorsky appointed to neurotech’s	1	0.22%
27	appointment of scott hunter	1	0.22%
28	skip to main menu	1	0.22%
29	scott hunter as chief	1	0.22%
30	for nt501 implant in	1	0.22%
31	medical officer authors article	1	0.22%
32	chief medical officer authors	1	0.22%
33	neurotech chief medical officer	1	0.22%
34	2022 read more neurotech	1	0.22%
35	mactel november 2 2022	1	0.22%
36	in mactel november 2	1	0.22%
37	implant in mactel november	1	0.22%
38	nt501 implant in mactel	1	0.22%
39	results for nt501 implant	1	0.22%
40	hunter as chief commercial	1	0.22%